New Insights on Long-Term Efficacy of Lecanemab Presented at 2026 AD/PD Congress

At the recent 2026 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD™) held in Copenhagen from March 17 to March 21, BioArctic and its partner Eisai presented promising new data regarding the long-term effectiveness of lecanemab in treating early Alzheimer's disease. The research primarily analyzed the treatment persistence among patients in the United States who were administered intravenous (IV) lecanemab.

The study, derived from the PurpleLab® claims database, revealed that a substantial proportion of patients maintained their lecanemab treatment beyond the initial 18 months. Specifically, 78.4% of participants continued their therapy at the 18-month mark, which slightly decreased to 71.7% at 20 months, and further to 67.3% at 24 months. Such high rates of treatment consistency are significant, as they suggest that extended treatment correlates with better clinical outcomes in patients suffering from chronic illnesses.

This trend of prolonged adherence is echoed in findings from the Phase 3 Clarity AD study, where a remarkable 94% of patients opted to enter the subsequent open-label extension (OLE) study following their initial 18 months of treatment. These ongoing users of lecanemab continued to reap benefits for up to four years compared to the natural progression of Alzheimer's disease as monitored by the Alzheimer’s Disease Neuroimaging Initiative (ADNI).

In addition to these findings, Professor Lars Lannfelt, co-founder of BioArctic, presented key insights into the binding profile of lecanemab within Alzheimer's brain tissue. His presentation highlighted how lecanemab selectively targets soluble amyloid-beta (Aβ) protofibrils, demonstrating robust mechanisms of action where it engages immune pathways that facilitate Aβ clearance from the brain.

Ebba Amandius from BioArctic also showcased a poster detailing a screening strategy implemented in a trial for exidavnemab concerning Parkinson's disease and multiple system atrophy. This study utilized an alpha-synuclein seed amplification assay (SAA) for effective patient stratification between treatment and placebo groups. The results supported the potential of SAA testing to enhance participant distribution and expedite the randomization process, thus emphasizing its importance in clinical trials focused on alpha-synuclein pathology.

Lecanemab is a product of BioArctic and Eisai's long-standing collaboration, with the antibody initially developed through Lannfelt's pioneering work on the Arctic mutation associated with Alzheimer's disease. This innovative collaboration has produced results that are currently under review for regulatory approval across various nations, enhancing the imperative efforts in combating this debilitating neurological disease.

While the data showcases the promise of lecanemab in real-world settings, it's essential to note that this report discusses investigational uses of the drug. Therefore, it cannot ascertain definitive conclusions around efficacy or safety at this stage, as further studies are required to navigate through the complexities of clinical development.

As we continue to witness advancements in Alzheimer's treatments, the partnership between BioArctic and Eisai stands as a testament to the innovation spurred by collaborative research efforts. As more findings are shared, they not only offer hope to patients and families affected by Alzheimer's disease but also lay the groundwork for future therapeutic strategies within the realm of neurodegenerative diseases.